# Ipamorelin Research: Mechanism and the Study Record | Ipamorelin > Ipamorelin research: the selective GH-secretagogue mechanism, the human PK study, the failed Phase 2 ileus trial, and recent ferret and review data — all cited. A clean GH pulse, one human PK dataset, one failed trial, and a thin recent literature. Each figure pinned to its source. ## The short version Ipamorelin makes the pituitary gland release a pulse of growth hormone, and it does so cleanly — without spiking the stress hormones cortisol and prolactin [1]. That selectivity is the headline of the science. Beyond it, the human record is thin: one study mapped how the drug moves through the body [2], and one mid-stage trial tested it for slow bowel recovery and failed [3]. Most of what is known comes from animals — rats and, recently, ferrets. Those studies show effects on bone growth and chemotherapy-related weight loss, but animals are not people, and short studies are not long ones. This page walks the mechanism, the key studies, and the open questions in plain terms, then keeps the technical depth below. ## What is ipamorelin peptide Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide — a chain of five amino acids — derived from GHRP-1 by removing its central Ala-Trp dipeptide. It carries an alpha-aminoisobutyric acid at position 1 and D-form amino acids that resist enzymatic breakdown, extending its life in plasma. Molecular formula C38H49N9O5, molecular weight about 711.9 daltons, CAS 170851-70-4, originally coded NNC 26-0161 at Novo Nordisk. It is wholly synthetic — not an endogenous human peptide — and works by mimicking ghrelin at the GHS-R1a receptor [1]. ## Mechanism: a selective GH pulse Ipamorelin selectively activates GHS-R1a (the ghrelin / growth hormone secretagogue receptor) on pituitary somatotrophs. Receptor activation runs through Gq/PLC signaling to raise intracellular calcium, which triggers GH release. The signature is selectivity: in the founding 1998 characterization it released GH potently in rat pituitary cells, anaesthetised rats, and conscious swine (swine ED50 2.3 ± 0.03 nmol/kg, versus 3.9 nmol/kg for GHRP-6), yet did not raise ACTH or cortisol above GHRH levels even at doses more than 200-fold above its GH ED50 — making it the first highly GH-selective secretagogue [1]. Because it works through the ghrelin receptor rather than the GHRH receptor, its action is distinct from and complementary to GHRH analogs. ## Ipamorelin cjc-1295 The pairing "ipamorelin cjc-1295" combines two growth-hormone-releasing peptides that act through different receptors. Ipamorelin works through the ghrelin / GHS-R1a receptor [1]; CJC-1295 is a GHRH analog acting through the GHRH receptor. The logic is two independent levers on one GH pulse. It is a pharmacological rationale, not a clinical one — no controlled human trial has tested the pair for any outcome, so the section below and the dosage page treat it as unproven, single-agent-supported combination chemistry. ## What is cjc 1295 ipamorelin The phrase "what is cjc 1295 ipamorelin" refers to pairing ipamorelin with CJC-1295, a GHRH analog. The two release growth hormone by different routes: ipamorelin through the ghrelin receptor [1], CJC-1295 through the GHRH receptor and its cAMP pathway. The rationale for combining them is mechanistic complementarity — two independent levers on the same GH pulse. That rationale is pharmacological, not clinical: there is no controlled human trial of the combination for any outcome, and the popular stack is supported by separate single-agent pharmacology, not by combination data. ## Does cjc-1295 ipamorelin work For the combination specifically, no controlled human trial has tested whether "cjc-1295 ipamorelin" works for any endpoint, so the honest answer is that combination efficacy is unproven. Each agent has its own pharmacology — ipamorelin reliably triggers a GH pulse in rodents, swine, and the single human PK study [1][2] — but a measurable GH pulse is not the same as a proven outcome in body composition, recovery, or aging. The one ipamorelin efficacy trial that reached a clinical endpoint, for postoperative ileus, failed [3]. ## The human evidence: PK study and a failed trial Human pharmacokinetics were characterized in healthy male volunteers (n=8 per dose; five 15-minute IV infusions of 4.21–140.45 nmol/kg). Kinetics were dose-proportional, with a terminal half-life of about 2 hours, clearance 0.078 L/h/kg, and steady-state volume of distribution 0.22 L/kg; the GH response peaked at roughly 0.67 h (40 minutes) as a single discrete pulse [2]. The only published Phase 2 RCT (NCT00672074) gave 0.03 mg/kg IV twice daily for up to seven days to 114 bowel-resection patients. It missed its primary endpoint — median time to first tolerated meal 25.3 h versus 32.6 h placebo (p=0.15) — with treatment-emergent adverse events in 87.5% of the ipamorelin arm versus 94.8% of placebo [3]. No Phase 3 trial has been conducted, and there is no approved indication. ## Preclinical findings: bone, body weight, the islet In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day (divided three times daily for 15 days) dose-dependently raised longitudinal bone growth rate from 42 µm/day in vehicle to 44, 50, and 52 µm/day, with no change in total IGF-1, IGFBPs, or bone turnover markers — indicating a partly local, GH-pulse-driven skeletal effect [4]. The freshest in-vivo study is a 2024 ferret experiment: intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48–72 h), but had no anti-emetic effect on either acute or delayed cisplatin-induced emesis, in contrast to centrally administered anamorelin, which cut acute emesis by 60% [5]. The effect on weight loss therefore appears peripheral. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a comparison of two mechanisms, not two doses. Sermorelin is a GHRH analog — it acts on the GHRH receptor to prompt GH release. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist acting through a different receptor entirely [1]. The two are sometimes paired for the same complementary reason ipamorelin is paired with CJC-1295. A regulatory contrast also separates them: sermorelin once had an approved formulation, whereas ipamorelin has never been approved for any indication [3]. This site does not name brand products; the comparison here is by mechanism and approval status only. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is likewise a class contrast. Tesamorelin is a GHRH analog. Ipamorelin works through the ghrelin receptor, a distinct route to the same GH pulse [1]. The sharpest difference is regulatory: one of these classes has a member with an approved human indication, while ipamorelin has none — its single Phase 2 trial failed and no approval followed anywhere [3]. As elsewhere on this site, the comparison stays at the level of mechanism and approval status, without naming any branded product. ## Where the literature is heading Recent reviews place ipamorelin firmly in the "unapproved, under-evidenced" column. A 2026 sports-medicine review of approved and unapproved peptides described it as an investigational GH-axis secretagogue with preclinical signals but no rigorous human trials and potential for serious harm [13]. A 2026 gerontology review grouped it with non-approved peptides lacking long-term safety data and validated monitoring frameworks [12]. A 2026 sports-medicine narrative review concluded there is no reproducible human evidence for musculoskeletal outcomes and recommended confining use to rigorous research protocols [15]. A broader 2026 review of metabolic and endocrine peptides stressed that further human studies are required before most new peptides can be used safely [14]. The recent literature is consistent: the mechanism is interesting, the human evidence is not yet there. --- A terminal-plain readout of where ipamorelin stands with regulators — never approved, banned in sport, compounding restricted, each line logged to source; no clinic behind the console and nothing here stocked, dispensed, or sold.